1-Methyl-3-hydroxy-hexahydroazepin | 19065-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1-Methyl-3-hydroxy-hexahydroazepin
• 英文别名: 1-methyl-azepan-3-ol；1-Methyl-3-hydroxyhexahydroazepine；1-methylazepan-3-ol
• CAS: 19065-47-5
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: QIRIHMCWPZKHGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRAZOLE KINASE FUSIONNEE TRICYCLIQUE ET TETRACYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2004080973A1

  公开（公告）日：2004-09-23

  Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有化学式(I) (I)的化合物对抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• Fused tri and tetra-cyclic pyrazole kinase inhibitors
  申请人：——

  公开号：US20040259904A1

  公开（公告）日：2004-12-23

  Compounds having the formula (I) 1 are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  化合物具有公式（I）1，对于抑制蛋白激酶具有用途。还公开了制备该化合物的方法，含有该化合物的组合物以及使用该化合物的治疗方法。
• Amidobenzamide derivatives which are useful as cytokine inhibitors
  申请人：Brown S. Dearg

  公开号：US20050038081A1

  公开（公告）日：2005-02-17

  The invention concerns amide derivatives of the Formula (I) wherein R 3 is (1-6C)alkyl or halogeno; Q is aryl or heteroaryl which optionally bears 1, 2, 3 or 4 substituents such as hydroxy, halogeno, trifluoromethyl, cyano, (1-6C)alkyl, (1-6C)alkoxy, halogeno-(1-6C)alkyl, hydroxyl-(1-6C)alkyl, di-[(1-6C)akly]amino-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, aryl-(1-6C)alkoxy, heteroaryl, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; p is 0-2 and R 2 is a substituent such as hydroxy and halogeno; q is 0-4; and R 4 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及公式（I）的酰胺衍生物，其中R3是（1-6C）烷基或卤素基; Q是芳基或杂环芳基，其可选地带有1、2、3或4个取代基，例如羟基、卤素基、三氟甲基、氰基、（1-6C）烷基、（1-6C）烷氧基、卤代（1-6C）烷基、羟基（1-6C）烷基、二-[(1-6C)烷基]氨基（1-6C）烷基、羟基（2-6C）烷氧基、（1-6C）烷氧基（2-6C）烷氧基、二-[(1-6C)烷基]氨基（2-6C）烷氧基、氨基（2-6C）烷基氨基、N-(1-6C)烷基-(1-6C)烷基氨基-(2-6C)烷基氨基、芳基、芳基-(1-6C)烷氧基、杂环芳基、杂环芳基-(1-6C)烷氧基、杂环基、杂环基-(1-6C)烷基、杂环氧基和杂环基-(1-6C)烷氧基; p为0-2，R2是羟基和卤素基等取代基; q为0-4; R4包括可选的取代芳基、环烷基、杂环芳基和杂环基; 或其药学上可接受的盐或体内可水解的酯; 以及制备它们的方法、包含它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗条件中的用途。
• BUFFER COMPOUNDS
  申请人：Haymore Barry L.

  公开号：US20120129240A1

  公开（公告）日：2012-05-24

  A method of buffering a chemical or biological composition, comprising adding to the composition an effective buffering amount of at least one protonated or un-protonated amine-quaternary ammonium compound having a general formula: wherein the variables R, G, n and k are as defined herein.

  一种化学或生物组成物的缓冲方法，包括向该组成物中添加至少一种质子化或非质子化的胺-季铵化合物，该化合物具有以下通式： 其中变量R、G、n和k的定义如本文所述，并且添加的量足以产生缓冲效应。
• NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：STENKAMP Dirk

  公开号：US20120010185A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中B、k、L、U、V、W、X、Y、Z、R1、R2的基团和基团具有权利要求1中给出的含义。此外，本发明还涉及含有至少一种根据本发明的化合物的制药组合物。由于它们的MCH受体拮抗活性，本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。